查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1172032

全球真实世界数据市场 (RWD)：按来源、按应用、按最终用户 - 预测（至 2029 年）

Real-world Data (RWD) by Source (EMR, Claims, Pharmacy, Disease Registries), Application [Market Access, Drug Development & Approvals (Oncology, Neurology), Post Market Surveillance], and End User (Pharma, Payers, Providers) - Global Forecast to 2029
出版日期: | 出版商: Meticulous Research | 英文 203 Pages | 订单完成后即时交付

价格

预计在 2022-2029 年的预测期内，全球真实世界数据 (RWD) 市场规模将以 7.4% 的复合年增长率增长，到 2029 年将达到 16.6 亿美元。. 推动市场增长的关键因素包括：慢性病负担加重、药物开发延误以及相关的开发成本上升、对个性化医疗的日益关注、转向基于价值的医疗、医疗保健行业，例如大数据的快速扩张在

本报告研究全球真实世界数据 (RWD) 市场，提供市场概况、市场规模和预测、趋势、驱动因素和製约因素、竞争格局、来源、应用和最终 我们提供特定于用户和特定区域的分析、公司简介等。

内容

第一章介绍

  • 市场定义
  • 市场生态系统
  • 货币

第二章研究方法论

  • 研究过程
  • 数据收集和验证
    • 二次调查
    • 初步调查
  • 市场评估
    • 市场规模估计
    • 市场份额分析
  • 调查先决条件
  • 调查限制

第 3 章执行摘要

第 4 章市场洞察

  • 市场概览
  • 司机
    • 提高对个性化医疗的认识
    • 药物开发的延迟和开发成本的伴随增加
    • 慢性病的负担越来越重
    • 转向基于价值的医学
    • 大数据在医疗保健领域迅速扩张
  • 约束因素
    • 不愿依赖现实世界的数据研究
  • 机会
    • 新兴国家
    • 对端到端 RWE 服务的兴趣与日俱增
  • 任务
    • 缺乏用于开发实际数据解决方案的标准化方法
  • 主要市场趋势
    • 在药物开发和商业化中扩大 RWD 的采用
    • 集成次数增加
  • COVID-19 对真实世界数据 (RWD) 市场的影响

第 5 章全球真实世界数据 (RWD) 市场：监管分析

  • 介绍
  • 北美
  • 欧洲
  • 亚太地区
  • 其他地区

第 6 章。全球真实世界数据 (RWD) 市场：按定价模型

  • 介绍
  • 按患者记录付费（基于数量的定价）
  • 即用即付（基于价值的定价）
  • 会员年费

第 7 章全球真实世界数据 (RWD) 市场：按来源

  • 介绍
  • EMR/EHR/临床数据
  • 账单/会计数据
  • 药房数据
  • 产品/疾病註册数据
  • 基因组数据
  • 其他

第 8 章。全球真实世界数据 (RWD) 市场：按应用

  • 介绍
  • 市场准入、赎回和适用范围的确定
  • 药物开发和审批
    • 肿瘤科
    • 神经学
    • 免疫学
    • 心血管疾病
    • 其他
  • 医疗器械的开发和审批
  • 上市后监督
  • 临床和监管决策

第 9 章。全球真实世界数据 (RWD) 市场：按最终用户分类

  • 介绍
  • 製药、生物技术和医疗设备公司
  • 医疗费用支付方
  • 医疗保健提供者
  • 其他

第 10 章真实世界数据 (RWD) 市场：按地区

  • 介绍
  • 北美
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 韩国
    • 台湾
    • 新加坡
    • 亚太其他地区
  • 拉丁美洲
  • 中东和非洲

第11章竞争格局

  • 介绍
  • 主要发展战略
  • 竞争基准
  • 市场份额分析（2021 年）
    • 艾昆纬控股公司
    • ICON plc
    • PPD 公司

第 12 章公司简介（业务概述、财务概述、解决方案组合、战略发展）

  • Clinigen Group plc
  • Cognizant Technology Solutions Corporation
  • Elevance Health, Inc.
  • Flatiron Health, Inc.
  • ICON plc
  • IQVIA Holdings Inc.
  • Oracle Corporation
  • PAREXEL International Corporation
  • PerkinElmer, Inc.
  • PPD Inc. (Subsidiary of Thermo Fisher Scientific Inc.)
  • SAS Institute Inc.
  • UnitedHealth Group Incorporated

第13章 附录

Product Code: MRHC - 104611

The real-world data (RWD) market is expected to grow at a CAGR of 7.4% from 2022 to 2029 to reach $1.66 billion by 2029.

Following a detailed secondary and primary research and an in-depth analysis of the market scenario, the report provides the key drivers, restraints, challenges, and opportunities in the real-world data (RWD) market.

The growing burden of chronic diseases, delays in drug development and the consequent increase in development costs, the rising attention towards personalized healthcare, the shift toward value-based care, and rapidly growing big data in the healthcare sector are the major drivers for the real-world data (RWD) market. However, the lack of standardized methodologies for developing real-world data solutions is a major challenge for market growth.

Based on source, the pharmacy data segment is slated to register the CAGR during the forecast period. The increasing focus on e-prescriptions and the volume of pharmacy data can serve as real-world data sources to help guide sales and market access strategy, provide data-driven insights to aid the payers' and HTAs' decision-making, maximize payer coverage, and improve patient outcomes.

Based on application, the drug development & approvals segment is slated to register the highest CAGR during the forecast period. RWD can be applied in drug development to support label expansion, optimize clinical use to support label revisions and meet postmarketing information and safety monitoring requirements. RWD insights can help accelerate the drug development & approvals process in a manner aligned with the interests of all stakeholders. Thus, the effective deployment of RWD can accelerate the pace of discovery, enable drug approvals, and help understand the impact of new therapies, thereby boosting the market's growth.

Based on end user, the pharmaceutical, biotechnology, and medical device companies segment is slated to register the highest CAGR during the forecast period. The increasing importance of real-world data studies in drug development & approvals and the growing need to avoid costly drug recalls and assess drug performance in real-world settings are driving the growth of this segment.

Based on geography, North America is expected to grow with the highest CAGR during the forecast period. The growth of this regional market is attributed to the increasing prevalence of chronic diseases, stringent regulations for drug approvals, implementation of the 21st Century Cures Act, availability of electronic datasets, the region's well-developed healthcare industry, and the increasing utilization of big data in healthcare.

Some of the key companies operating in the global RWD market are Elevance Health, Inc. (U.S.), IQVIA Holdings Inc. (U.S.), ICON plc (Ireland), PPD Inc. (U.S.), Clinigen Group plc (U.K.), Cognizant Technology Solutions Corporation (U.S.), Oracle Corporation (U.S.), PAREXEL International Corporation (U.S.), PerkinElmer, Inc. (U.S.), SAS Institute Inc. (U.S.), UnitedHealth Group Incorporated (U.S.), and Flatiron Health, Inc. (U.S.).

Scope of the Report:

Global Real-world Data Market, by Source

  • EMR/EHR/Clinical Data
  • Claims & Billing Data
  • Pharmacy Data
  • Product/Disease Registries Data
  • Genomics Data
  • Other Datasets

Note: Other sources include data gathered from other sources, such as mobile devices, wearable devices, and social media, which can provide information on health status.

Global Real-world Data Market, by Application

  • Market Access & Reimbursement/Coverage Decisions
  • Drug Development & Approvals
  • Oncology
  • Neurology
  • Immunology
  • Cardiovascular Diseases
  • Other Therapeutic Areas
  • Post-market Surveillance
  • Medical Device Development & Approvals
  • Regulatory and Clinical Decision-making

Note: Other Therapeutic Areas include infectious diseases, musculoskeletal disorders, dermatological diseases, and respiratory diseases.

Global Real-world Data Market, by End User

  • Pharmaceutical, Biotechnology, and Medical Device Companies
  • Healthcare Payers
  • Healthcare Providers
  • Other End Users

Note: Other end users include academic research institutions, patient advocacy groups, regulators, and health technology assessment agencies.

Global Real-world Data Market, by Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
    • Rest of Europe (RoE)
  • Asia-Pacific (APAC)
    • Japan
    • China
    • India
    • South Korea
    • Taiwan
    • Singapore
    • Rest of APAC (RoAPAC)
  • Latin America
  • Middle East & Africa

TABLE OF CONTENTS

1. Introduction

  • 1.1. Market Definition
  • 1.2. Market Ecosystem
  • 1.3. Currency

2. Research Methodology

  • 2.1. Research Process
  • 2.2. Data Collection & Validation
    • 2.2.1. Secondary Research
    • 2.2.2. Primary Research
  • 2.3. Market Assessment
    • 2.3.1. Market Size Estimation
      • 2.3.1.1. Bottom-up Approach
      • 2.3.1.2. Top-down Approach
      • 2.3.1.3. Growth Forecast
    • 2.3.2. Market Share Analysis
  • 2.4. Assumptions for the Study
  • 2.5. Limitations for the Study

3. Executive Summary

4. Market Insights

  • 4.1. Market Overview
  • 4.2. Drivers
    • 4.2.1. Rising Awareness of Personalized Healthcare
    • 4.2.2. Delay in Drug Development and the Consequent Increase in Development Costs
    • 4.2.3. Growing Burden of Chronic Diseases
    • 4.2.4. Shift toward Value-based Care
    • 4.2.5. Rapidly Growing Big Data in the Healthcare Sector
  • 4.3. Restraints
    • 4.3.1. Reluctance to Rely on Real-world Data Studies
  • 4.4. Opportunities
    • 4.4.1. Emerging Economies
    • 4.4.2. Rising Focus on End-to-end RWE Services
  • 4.5. Challenges
    • 4.5.1. Lack of Standardized Methodologies for Developing Real-world Data Solutions
  • 4.6. Key Market Trends
    • 4.6.1. Growing Adoption of RWD in Drug Development and Commercialization
    • 4.6.2. Rising Number of Consolidations
  • 4.7. The Impact of COVID-19 on the Real-world Data Market

5. Global Real-world Data Market: Regulatory Analysis

  • 5.1. Introduction
  • 5.2. North America
  • 5.3. Europe
  • 5.4. Asia-Pacific
  • 5.5. Rest of the World

6. Global Real-world Data Market, by Pricing Model

  • 6.1. Introduction
  • 6.2. Pay-per-patient Record (Volume-based Pricing)
  • 6.3. Pay-per-usage (Value-based Pricing)
  • 6.4. Annual Subscription

7. Global Real-world Data Market, by Source

  • 7.1. Introduction
  • 7.2. EMR/EHR/Clinical Data
  • 7.3. Claims & Billing Data
  • 7.4. Pharmacy Data
  • 7.5. Product/Disease Registries Data
  • 7.6. Genomics Data
  • 7.7. Other Sources

8. Global Real-world Data Market, by Application

  • 8.1. Introduction
  • 8.2. Market Access & Reimbursement/Coverage Decision
  • 8.3. Drug Development & Approvals
    • 8.3.1. Oncology
    • 8.3.2. Neurology
    • 8.3.3. Immunology
    • 8.3.4. Cardiovascular Diseases
    • 8.3.5. Other Therapeutic Areas
  • 8.4. Medical Device Development & Approvals
  • 8.5. Post-market Surveillance
  • 8.6. Clinical & Regulatory Decision-Making

9. Global Real-world Data Market, by End User

  • 9.1. Introduction
  • 9.2. Pharmaceutical, Biotechnology, and Medical Device Companies
  • 9.3. Healthcare Payers
  • 9.4. Healthcare Providers
  • 9.5. Other End Users

10. Real-world Data Market, by Geography

  • 10.1. Introduction
  • 10.2. North America
    • 10.2.1. U.S.
    • 10.2.2. Canada
  • 10.3. Europe
    • 10.3.1. U.K.
    • 10.3.2. Germany
    • 10.3.3. France
    • 10.3.4. Italy
    • 10.3.5. Spain
    • 10.3.6. Rest of Europe (RoE)
  • 10.4. Asia-Pacific
    • 10.4.1. Japan
    • 10.4.2. China
    • 10.4.3. India
    • 10.4.4. South Korea
    • 10.4.5. Taiwan
    • 10.4.6. Singapore
    • 10.4.7. Rest of Asia-Pacific (RoAPAC)
  • 10.5. Latin America
  • 10.6. Middle East & Africa

11. Competitive Landscape

  • 11.1. Introduction
  • 11.2. Key Growth Strategies
  • 11.3. Competitive Benchmarking
  • 11.4. Market Share Analysis (2021)
    • 11.4.1. IQVIA Holdings Inc. (U.S.)
    • 11.4.2. ICON plc (Ireland)
    • 11.4.3. PPD Inc. (U.S.)

12. Company Profiles (Business Overview, Financial Overview, Solution Portfolio, Strategic Developments)

  • 12.1. Clinigen Group plc
  • 12.2. Cognizant Technology Solutions Corporation
  • 12.3. Elevance Health, Inc.
  • 12.4. Flatiron Health, Inc.
  • 12.5. ICON plc
  • 12.6. IQVIA Holdings Inc.
  • 12.7. Oracle Corporation
  • 12.8. PAREXEL International Corporation
  • 12.9. PerkinElmer, Inc.
  • 12.10. PPD Inc. (Subsidiary of Thermo Fisher Scientific Inc.)
  • 12.11. SAS Institute Inc.
  • 12.12. UnitedHealth Group Incorporated

13. Appendix

  • 13.1. Questionnaire
  • 13.2. Available Customization

List of Tables

  • Table 1 Global Real-world Data Market Drivers: Impact Analysis (2022-2029)
  • Table 2 Total Cost Per Study, by Phase and Therapeutic Area (USD Million)
  • Table 3 Number of Persons Aged 65 Years or Above, by Region (2019 Vs. 2050)
  • Table 4 Sources of Healthcare Data
  • Table 5 Global Real-world Data Market Restraints: Impact Analysis (2022-2029)
  • Table 6 Real-world Data in Latin American Countries
  • Table 7 Observed Indicative Prices of Real-world Data by Type (USD Per Patient Record)
  • Table 8 Global Real-world Data Market Size, by Source, 2020-2029 (USD Million)
  • Table 9 Global Real-world Data Market Size for EMR/EHR/Clinical Data, by Country/Region, 2020-2029 (USD Million)
  • Table 10 Global Real-world Data Market Size for Claims & Billing Data, by Country/Region, 2020-2029 (USD Million)
  • Table 11 Global Real-world Data Market Size for Pharmacy Data, by Country/Region, 2020-2029 (USD Million)
  • Table 12 Global Real-world Data Market Size for Product/Disease Registries Data, by Country/Region, 2020-2029 (USD Million)
  • Table 13 Global Real-world Data Market Size for Genomics Data, by Country/Region, 2020-2029 (USD Million)
  • Table 14 Global Real-world Data Market Size for Other Sources, by Country/Region, 2020-2029 (USD Million)
  • Table 15 Global Real-world Data Market Size, by Application, 2020-2029 (USD Million)
  • Table 16 Global Real-world Data Market Size for Access & Reimbursement/Coverage Decision, by Country/Region, 2020-2029 (USD Million)
  • Table 17 Global Real-world Data Market Size for Drug Development & Approvals, by Therapeutic Area, 2020-2029 (USD Million)
  • Table 18 Global Real-world Data Market Size for Drug Development & Approvals, by Country/Region, 2020-2029 (USD Million)
  • Table 19 Oncology: Drugs in the R&D Pipeline
  • Table 20 Global Drug Development & Approvals Market Size for Oncology, by Country/Region, 2020-2029 (USD Million)
  • Table 21 Neurology: Drugs in the R&D Pipeline
  • Table 22 Global Drug Development & Approvals Market Size for Neurology, by Country/Region, 2020-2029 (USD Million)
  • Table 23 Immunology: Drugs in the R&D Pipeline
  • Table 24 Global Drug Development & Approvals Market Size for Immunology, by Country/Region, 2020-2029 (USD Million)
  • Table 25 Medical Costs Associated With Cardiovascular Diseases (2010-2030) (USD Billion)
  • Table 26 Cardiovascular Diseases: Drugs in the R&D Pipeline
  • Table 27 Global Drug Development & Approvals Market Size for Cardiovascular Diseases, by Country/Region, 2020-2029 (USD Million)
  • Table 28 Other Therapeutic Areas: Drugs in the R&D Pipeline
  • Table 29 Global Drug Development & Approvals Market Size for Other Therapeutic Areas, by Country/Region, 2020-2029 (USD Million)
  • Table 30 Global Real-world Data Market Size for Medical Device Development & Approvals, by Country/Region, 2020-2029 (USD Million)
  • Table 31 Global Real-world Data Market Size for Post-market Surveillance, by Country/ Region, 2020-2029 (USD Million)
  • Table 32 Global Real-world Data Market Size for Clinical & Regulatory Decision-Making, by Country/Region, 2020-2029 (USD Million)
  • Table 33 Global Real-world Data Market Size, by End User, 2020-2029 (USD Million)
  • Table 34 Global Real-world Data Market Size for Pharmaceutical, Biotechnology, and Medical Device Companies, by Country/Region, 2020-2029(USD Million)
  • Table 35 Global Real-world Data Market Size for Healthcare Payers, by Country/Region, 2020-2029 (USD Million)
  • Table 36 Global Real-world Data Market Size for Healthcare Providers, by Country/Region, 2020-2029 (USD Million)
  • Table 37 Global Real-world Data Market Size for Other End Users, by Country/Region, 2020-2029 (USD Million)
  • Table 38 Global Real-world Data Market Size, by Country/Region, 2020-2029 (USD Million)
  • Table 39 North America: Real-world Data Market Size, by Country, 2020-2029 (USD Million)
  • Table 40 North America: Real-world Data Market Size, by Source, 2020-2029 (USD Million)
  • Table 41 North America: Real-world Data Market Size, by Application, 2020-2029 (USD Million)
  • Table 42 North America: Real-world Data Market Size for Drug Development & Approvals, by Therapeutic Area, 2020-2029 (USD Million)
  • Table 43 North America: Real-world Data Market Size, by End User, 2020-2029 (USD Million)
  • Table 44 U.S.: Real-world Data Market Size, by Source, 2020-2029 (USD Million)
  • Table 45 U.S.: Real-world Data Market Size, by Application, 2020-2029 (USD Million)
  • Table 46 U.S.: Real-world Data Market Size for Drug Development & Approvals, by Therapeutic Area, 2020-2029 (USD Million)
  • Table 47 U.S.: Real-world Data Market Size, by End User, 2020-2029 (USD Million)
  • Table 48 Number of Active Clinical Trials in Canada, by Condition (2020)
  • Table 49 Canada: Real-world Data Market Size, by Source, 2020-2029 (USD Million)
  • Table 50 Canada: Real-world Data Market Size, by Application, 2020-2029 (USD Million)
  • Table 51 Canada: Real-world Data Market Size for Drug Development & Approvals, by Therapeutic Area, 2020-2029 (USD Million)
  • Table 52 Canada: Real-world Data Market Size, by End User, 2020-2029 (USD Million)
  • Table 53 Europe: Real-world Data Market Size, by Country/Region, 2020-2029 (USD Million)
  • Table 54 Europe: Real-world Data Market Size, by Source, 2020-2029 (USD Million)
  • Table 55 Europe: Real-world Data Market Size, by Application, 2020-2029 (USD Million)
  • Table 56 Europe: Real-world Data Market Size for Drug Development & Approvals, by Therapeutic Area, 2020-2029 (USD Million)
  • Table 57 Europe: Real-world Data Market Size, by End User, 2020-2029 (USD Million)
  • Table 58 U.K.: Conferences and Workshops on Real-world Data Solutions
  • Table 59 U.K.: Real-world Data Market Size, by Source, 2020-2029 (USD Million)
  • Table 60 U.K.: Real-world Data Market Size, by Application, 2020-2029 (USD Million)
  • Table 61 U.K.: Real-world Data Market Size for Drug Development & Approvals, by Therapeutic Area, 2020-2029 (USD Million)
  • Table 62 U.K.: Real-world Data Market Size, by End User, 2020-2029 (USD Million)
  • Table 63 Conferences, Symposia, and Workshops in Germany
  • Table 64 Germany: Real-world Data Market Size, by Source, 2020-2029 (USD Million)
  • Table 65 Germany: Real-world Data Market Size, by Application, 2020-2029 (USD Million)
  • Table 66 Germany: Real-world Data Market Size for Drug Development & Approvals, by Therapeutic Area, 2020-2029 (USD Million)
  • Table 67 Germany: Real-world Data Market Size, by End User, 2020-2029 (USD Million)
  • Table 68 France: Real-world Data Market Size, by Source, 2020-2029 (USD Million)
  • Table 69 France: Real-world Data Market Size, by Application, 2020-2029 (USD Million)
  • Table 70 France: Real-world Data Market Size for Drug Development & Approvals, by Therapeutic Area, 2020-2029 (USD Million)
  • Table 71 France: Real-world Data Market Size, by End User, 2020-2029 (USD Million)
  • Table 72 Italy: Real-world Data Market Size, by Source, 2020-2029 (USD Million)
  • Table 73 Italy: Real-world Data Market Size, by Application, 2020-2029 (USD Million)
  • Table 74 Italy: Real-world Data Market Size for Drug Development & Approvals, by Therapeutic Area, 2020-2029 (USD Million)
  • Table 75 Italy: Real-world Data Market Size, by End User, 2020-2029 (USD Million)
  • Table 76 Spain: Real-world Data Market Size, by Source, 2020-2029 (USD Million)
  • Table 77 Spain: Real-world Data Market Size, by Application, 2020-2029 (USD Million)
  • Table 78 Spain: Real-world Data Market Size for Drug Development & Approvals, by Therapeutic Area, 2020-2029 (USD Million)
  • Table 79 Spain: Real-world Data Market Size, by End User, 2020-2029 (USD Million)
  • Table 80 Rest of Europe: Real-world Data Market Size, by Source, 2020-2029 (USD Million)
  • Table 81 Rest of Europe: Real-world Data Market Size, by Application, 2020-2029 (USD Million)
  • Table 82 Rest of Europe: Real-world Data Market Size for Drug Development & Approvals, by Therapeutic Area, 2020-2029 (USD Million)
  • Table 83 Rest of Europe: Real-world Data Market Size, by End User, 2020-2029 (USD Million)
  • Table 84 Asia-Pacific: Real-world Data Market Size, by Country/Region, 2020-2029 (USD Million)
  • Table 85 Asia-Pacific: Real-world Data Market Size, by Source, 2020-2029 (USD Million)
  • Table 86 Asia-Pacific: Real-world Data Market Size, by Application, 2020-2029 (USD Million)
  • Table 87 Asia-Pacific: Real-world Data Market Size for Drug Development & Approvals, by Therapeutic Area, 2020-2029 (USD Million)
  • Table 88 Asia-Pacific: Real-world Data Market Size, by End User, 2020-2029 (USD Million)
  • Table 89 Japan: Real-world Data Market Size, by Source, 2020-2029 (USD Million)
  • Table 90 Japan: Real-world Data Market Size, by Application, 2020-2029 (USD Million)
  • Table 91 Japan: Real-world Data Market Size for Drug Development & Approvals, by Therapeutic Area, 2020-2029 (USD Million)
  • Table 92 Japan: Real-world Data Market Size, by End User, 2020-2029 (USD Million)
  • Table 93 China: Diversified Real-world Data Sources
  • Table 94 China: Real-world Data Market Size, by Source, 2020-2029 (USD Million)
  • Table 95 China: Real-world Data Market Size, by Application, 2020-2029 (USD Million)
  • Table 96 China: Real-world Data Market Size for Drug Development & Approvals, by Therapeutic Area, 2020-2029 (USD Million)
  • Table 97 China: Real-world Data Market Size, by End User, 2020-2029 (USD Million)
  • Table 98 India: Real-world Data Market Size, by Source, 2020-2029 (USD Million)
  • Table 99 India: Real-world Data Market Size, by Application, 2020-2029 (USD Million)
  • Table 100 India: Real-world Data Market Size for Drug Development & Approvals, by Therapeutic Area, 2020-2029 (USD Million)
  • Table 101 India: Real-world Data Market Size, by End User, 2020-2029 (USD Million)
  • Table 102 South Korea: Real-world Data Market Size, by Source, 2020-2029 (USD Million)
  • Table 103 South Korea: Real-world Data Market Size, by Application, 2020-2029 (USD Million)
  • Table 104 South Korea: Real-world Data Market Size for Drug Development & Approvals, by Therapeutic Area, 2020-2029 (USD Million)
  • Table 105 South Korea: Real-world Data Market Size, by End User, 2020-2029 (USD Million)
  • Table 106 Taiwan: Rwe Sources
  • Table 107 Taiwan: Real-world Data Market Size, by Source, 2020-2029 (USD Million)
  • Table 108 Taiwan: Real-world Data Market Size, by Application, 2020-2029 (USD Million)
  • Table 109 Taiwan: Real-world Data Market Size for Drug Development & Approvals, by Therapeutic Area, 2020-2029 (USD Million)
  • Table 110 Taiwan: Real-world Data Market Size, by End User, 2020-2029 (USD Million)
  • Table 111 Singapore: Real-world Data Market Size, by Source, 2020-2029 (USD Million)
  • Table 112 Singapore: Real-world Data Market Size, by Application, 2020-2029 (USD Million)
  • Table 113 Singapore: Real-world Data Market Size for Drug Development & Approvals, by Therapeutic Area, 2020-2029 (USD Million)
  • Table 114 Singapore: Real-world Data Market Size, by End User, 2020-2029 (USD Million)
  • Table 115 Estimated Number of New Cancer Cases From 2020 To 2030
  • Table 116 Rest of Asia-Pacific: Real-world Data Market Size, by Source, 2020-2029 (USD Million)
  • Table 117 Rest of Asia-Pacific: Real-world Data Market Size, by Application, 2020-2029 (USD Million)
  • Table 118 Rest of Asia-Pacific: Real-world Data Market Size for Drug Development & Approvals, by Therapeutic Area, 2020-2029 (USD Million)
  • Table 119 Rest of Asia-Pacific: Real-world Data Market Size, by End User, 2020-2029 (USD Million)
  • Table 120 Latin America: Real-world Data Market Size, by Source, 2020-2029 (USD Million)
  • Table 121 Latin America: Real-world Data Market Size, by Application, 2020-2029 (USD Million)
  • Table 122 Latin America: Real-world Data Market Size for Drug Development & Approvals, by Therapeutic Area, 2020-2029 (USD Million)
  • Table 123 Latin America: Real-world Data Market Size, by End User, 2020-2029 (USD Million)
  • Table 124 Middle East & Africa: Real-world Data Market Size, by Source, 2020-2029 (USD Million)
  • Table 125 Middle East & Africa: Real-world Data Market Size, by Application, 2020-2029 (USD Million)
  • Table 126 Middle East & Africa: Real-world Data Market Size for Drug Development & Approvals, by Therapeutic Area, 2020-2029 (USD Million)
  • Table 127 Middle East & Africa: Real-world Data Market Size, by End User, 2020-2029 (USD Million)
  • Table 128 Recent Developments, by Company, 2018-2021

List of Figures

  • Figure 1 Key Stakeholders
  • Figure 2 Research Process
  • Figure 3 Key Secondary Sources
  • Figure 4 Primary Research Techniques
  • Figure 5 Key Executives Interviewed
  • Figure 6 Breakdown of Primary Interviews (Supply-Side & Demand-Side)
  • Figure 7 Market Size Estimation
  • Figure 8 Global Real-world Data Market, by Source, 2022 Vs. 2029 (USD Million)
  • Figure 9 Global Real-world Data Market, by Application, 2022 Vs. 2029 (USD Million)
  • Figure 10 Global Real-world Data Market, by End User, 2022 Vs. 2029 (USD Million)
  • Figure 11 Global Real-world Data Market, by Geography
  • Figure 12 Market Dynamics
  • Figure 13 Percentage of Personalized Medicines Approved (2015-2020)
  • Figure 14 U.S.: Number of People With Chronic Conditions (2000-2030)
  • Figure 15 Asia-Pacific: Percent Share of Global Clinical Trial Activities (2012-2020)
  • Figure 16 Global Real-world Data Market Size, by Source, 2022 Vs. 2029 (USD Million)
  • Figure 17 U.S.: Number of E-Prescriptions, 2013-2020 (In Billion)
  • Figure 18 Global Real-world Data Market Size, by Application, 2022 Vs. 2029 (USD Million)
  • Figure 19 Estimated Number of New Cancer Cases, by Region, 2020-2040 (In Million)
  • Figure 20 Global Real-world Data Market Size, by End User, 2022 Vs. 2029 (USD Million)
  • Figure 21 Pharmaceutical R&D Spending, 2012-2026 (USD Billion)
  • Figure 22 Global Real-world Data Market Size, by Region, 2022 Vs. 2029 (USD Million)
  • Figure 23 North America: Real-world Data Market Snapshot
  • Figure 24 Number of Novel Drugs Approved by the CDER (2010-2021)
  • Figure 25 Europe: Real-world Data Market Snapshot
  • Figure 26 Germany: Pharmaceutical R&D Expenditure, 2016-2020 (USD Million)
  • Figure 27 France: Share of the Population Aged 65 Years & Above (2010-2020)
  • Figure 28 Italy: Share of the Population Aged 65 Years and Above (2015-2020)
  • Figure 29 Spain: Pharmaceutical R&D Expenditure, 2016-2020 (USD Million)
  • Figure 30 Pharmaceutical R&D Expenditure in European Countries, 2016-2020 (USD Million)
  • Figure 31 Asia-Pacific: Real-world Data Market Snapshot
  • Figure 32 Japan: Number of People Below 65 Years of Age (2000-2050)
  • Figure 33 Key Growth Strategies Adopted by Leading Players (2018-2022)
  • Figure 34 Real-world Data Market: Competitive Benchmarking, by Geography
  • Figure 35 Market Share Analysis: Real-world Data Industry (2021)
  • Figure 36 Financial Overview (2019-2021): IQVIA Holdings Inc.
  • Figure 37 Financial Overview (2018-2020): PPD Inc.
  • Figure 38 Financial Overview (2019-2021): ICON plc
  • Figure 39 Financial Overview (2019-2021): UnitedHealth Group Incorporated
  • Figure 40 Financial Overview (2019-2021): Oracle Corporation
  • Figure 41 Financial Overview (2020-2021): SAS Institute Inc.
  • Figure 42 Financial Overview (2019-2021): Elevance Health, Inc.
  • Figure 43 Financial Overview (2019-2021): Clinigen Group plc
  • Figure 44 Financial Overview (2019-2021): Cognizant Technology Solutions Corporation
  • Figure 45 Financial Overview (2019-2022): PerkinElmer, Inc.